Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 321-329

  Kolb, Hans Jochem ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; HUMAN; LEUKOCYTE TRANSFUSION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL;

EID: 0031849164     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05438.x     Document Type: Conference Paper

References (72)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation, N Engl J Med 1975;292:832-843.
2. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, Goodell BW, Hickman RO, Lerner KG., Neiman PE, Sale GE, Sanders JE, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood 1977;49:511-533.
3. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, et al Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-1728.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
5. Horowitz MM: New IBMTR/ABMTR Slides Summarize Current Use and Outcome of Allogeneic and Autologous Transplants. IBMTR Newsletter. IBMTR Statistical Center. 1995; 2(1). 2-8. Milwaukee.
6. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Blume KG, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AM, et al. Bone marrow transplantation for acute lymphoblastic leukemia: Factors influencing relapse and survival. Blood 1989;74:862
7. Gale RP, Butturini A, Horowitz MM: HLA-identical sibling bone marrow transplants for acute lymphoblastic leukemia. Bone Marrow Transplant 1995;15 Suppl 1-.S199-S202.
8. Barnes DHW, Loutit JF: Treatment of murine leukaemia with X-rays and homologous bone marrow, Br J Haematol 1957;3:241-252.
9. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M: Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 1965;25;1525-1530.
10. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation, N Engl J Med 1981;304:1529-1531.
11. Weiden PL, Storb R, Tsoi M-S, Graham TC, Lerner KG, Thomas ED: Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J Immunol 1976;116:1212-1219.
12. Kolb HJ, Günther W, Schumm M, Holler E, Wilmanns W, Thierfelder S: Adoptive immunotherapy in canine chimeras, Transplantation 1997;63:1-7.
13. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993;11:329-336.
14. Kolb HJ, Mittermueller J, Clemm C, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
15. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermüller J, et al. Graftversus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
16. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
17. van Rhee F, Goldman JM: ; Morstyn G, Sheridan W, editors.Cell Therapy - Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy. first ed. Cambridge: Cambridge University Press, 1996; 30, Donor lymphocyte therapy in bone marrow transplantation, p. 550-67.
18. van Rhee F, Goldman JM: ; Morstyn G, Sheridan W, editors.Cell Therapy - Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy. first ed. Cambridge: Cambridge University Press, 1996; 30, Donor lymphocyte therapy in bone marrow transplantation, p. 550-67.
19. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, CastroMalaspina H, Childs BH, Gillio AP, Kernan NA, Small TM, Young JW, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
20. Arcese W, Mauro FR, Alimena G, LoCoco F, DeCuia MR, Screni M, Iori AP, Montefusco B, Mandelli F: Interferon therapy for Phlpositive CML patients relapsing after T-cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;5:309
21. Arcese W, Goldman JM, DArcangelo E, Schattenberg A, Nardi A, Apperley JF, Frassoni F, Aversa F, Prentice HG, Ljungman P, Ferrant A, Marosi C, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993;82:3211-3219.
22. Higano CS, Raskind WH, Singer JW: Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic marrow transplantation. Blood 1992;80:1437
23. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M: Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991;78:499-505.
24. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK: The interferons -Mechanism of action and clinical applications. JAMA 1991;266:1375-1383.
25. Palva IP, Almqvist A, Elonen E, Hanninen A, Jouppila J, Jarventie G, Koivunen E, Katka K, Lathinen R, Oivanen T, et al. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukemia. Eur J Haematol 1991;47:229-233.
26. Lönnqvist B, Brune M, Ljungman P: Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML - a case report. Bone Marrow Transplant 1996;18:241-242.
27. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-2204.
28. Odom L, Githers J, Morse H, Sharna B, August CS, Humbert J, Peakman D, Rosnak S, Johnson F: Remission of relapsed leukemia during a graft-versus-host reaction, A graftversus-leukemia reaction in man? Lancet 1978;2:537
29. Higano CS, Brixey M, Bryant EM, Durnam DM, Doney K, Sullivan KM, Singer JW: Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation: A case report of a probable graft-versus-leukemia effect. Transplantation 1990;50:175-177.
30. Collins RHJ, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992;10:391-395.
31. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ: Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic rnyeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995;15:591-594.
32. Schattenberg A, van de Wiel-van Kemenade E, Schaap N, De Witte T: Chimerism and out-come of the infusion of lymphocytes as a treatment for relapse after T cell depleted BMT. Bone Marrow Transplant 1996;17 SuppI 1;S9-abstr
33. Schattenberg A, van de Wiel-van Kemenade E, Schaap N, De Witte T: Chimerism status of T-lymphocytes at the time of relapse predicts outcome of donor lymphocyte transfusions for tretament of relapse after allogeneic BMT. [Abstract] Bone Marrow Transplant 1997;19:(Supp11)S68
34. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-4343.
35. Alyea EP, Canning C, Collins H, Pickett C, Wang Y, Soiffer R, Ritz J: Efficacy and toxicity of CD4 positive donor T-lymphocyte transfusion for treatment of relapsed chronic myelogenous leukemia (CML) after allogeneic BMT, [Abstract] Blood 1996;88 Suppl 1:682a
36. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host disease. N Engl J Med 1990;323:315
37. Flowers MED, Sullivan KM, Martin P, Buckner CD, Beach K, Higano T, Radich JP, Clift RA, Bensinger W, Deeg HJ, Chauncey TR, Rowley S, et al. G-CSF stimulated donor peripheral blood infusions as immunotherapy in patients with hematologic malignancies relapsing after allogeneic transplantation. [Abstract] Blood 1995;86:(Suppl. 1)564a
38. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EF: Graft-versusmyeloma effect in two cases. Lancet 1996;347:800-801.
39. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 1996;87:1196-1198.
40. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:975-980.
41. Barrett AJ, Joshi R, Tew C: How should acute lymphoblastic leukaemia relapsing after bone marrow transplantation be treated? Lancet 1985;1:1188-1191.
42. Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ, Prentice HG, Vernant JP, Zwaan FE, Gratwohl A: Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988;70:317-320.
43. Mittermueller J, Kolb HJ, Gerhartz HH, Wilmanns W: In vivo differentiation of leukemic blasts and effect of low dose ara-c in a marrow grafted patient with leukemic relapse. Brit J Haematol 1986;62:757-762.
44. Mittermüller J, Kolb HJ, Clemm C, Holler E, Hartwig R, Gleixner B, Mönch K, Wilmanns W: Chimerism and treatment of recurrent leukemia after marrow transplantation. Cancer Res Clin Oncol 1990;116:577
45. Bekassy AN, Hermans J, Gorin NC, Gratwohl A, EBMT: Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Bone Marrow Transplant 1996;17:801-808.
46. Chak L, Sapozink M, Cox R: Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy, Int J Rad One Biol Phys 1983;9:1173
47. Bowman W, Aur R, Hustu H, Rivera G: Isolated testicular relapse relapse in acute lymphocytic leukemia of childhood: Categories and influence on survival. J Clin Oncol 1984;2:924
48. Giralt S, Escudier S, Kantarijan H, et al. Preliminary results of treatment with filgastrim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993;329:757-761.
49. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994;84:3603-3612.
50. Metcalf D: Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells. Int J Cancer 1979;24:616-623.
51. Widmer-Pack MD, Olivier W, Valinski J, Schuler G, Steinman RM: Granulocytemacrophage colony stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987;166:1494-1498.
52. Pan L, Delmonte J, Jalonen CK, Ferrara JLM: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422
53. Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987;38:2718-2727.
54. Charak BS, Brynes RK, Chogyoji M, Kortes V, Tefft M, Mazumder A: Graft versus leukemia effect after transplantation with interleukin-2-activated bone marrow. Correlation with eradication of residual disease. Transplantation 1993;56:31-37.
55. Soiffer R, Murray C, Cochran K, Cameron C, Wang E, Scnow P, Daly J, Ritz J: Clinical and immunological effects of prolonged infusions of low dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 1992;79:517
56. Verdonck LF, van Heugten HG, Giltay J, Franks CR: Amplification of the graft-versusleukemia effect in man by interleukin-2. Transplantation 1991;51:1120-1124.
57. Charak BS, Choudary G, Tefft M, Mazumder A: Interleukin-2 in bone marrow transplantation: Preclinical studies. Bone Marrow Transplant 1992;10:103-111.
58. Fefer A, Benyunes MC, York A, Buckner CD, Thompson JA: Use of interleukin-2 after bone marrow transplantation. Bone Marrow Transplant 1995;15 Suppl 1;S162-S166.
59. Biaise D, Olive D, Stoppa A, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation for hematological malignancies. Blood 1990;76:1092-1097.
60. Foa R, Meloni G, Tosti S, Novarino A, Fern S, Gavosta F: Treatment of acute myelogenous leukaemia patients with recombinant interleukin-2: A pilot study. Brit J Haematol 1991;77:491
61. Huang AYC, Golumbek P, Ahmadzadeh M, Jaftee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells presenting MHC class I- restricted tumor antigens. Science 1994;264:961-965.
62. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
63. Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G, Gianni AM: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-1467.
64. Kolb HJ, enzel H, Holler E, Verdonck L, Bunjes D, Schattenberg A, Apperley JF, Ljungman P, Jacobsen N, Ferrant A: Donor cells transfusion for the treatment of rercurrent leukemia after allogeneic bone marrow transplantation. [Abstract] Blood 1997;90:(suppl 1)546a-2434.
65. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barren AJ: T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993;11:133-138.
66. Bunjes D, Hertenstein B, Wiesneth M, Novotny J, Frickhofen N, Arnold R, Heimpel H: Donor lymphocyte transfusions and low-dose interleukin-2 in 2 patients with relapsed CML after syngeneic BMT. Bone Marrow Transplant 1996;17 Suppl 1:S9-abtsr.
67. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-3592.
68. Mannering SI, McKenzie JL, Hart DN: Generation of T-lymphocyte clones specific for the BCR-ABL fusion peptide presented by dendritic cells and other antigen presenting cells. [Abstract] Bone Marrow Transplant 1996;17Suppl1:S59
69. Mutis T, Schrama E, van Luxemburg Heijs SA, Falkenburg JHF, Melief CJ, Goulmy E: HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells. Blood 1997;90:1083-1090.
70. Voogt PJ, Goulmy E, Veenhof WFJ, Hamilton M, Fibbe WE, Van Rood JJ, Falkenburg JHF: Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 1988;168:2337-2347.
71. Bonini C, Ferrari G, Verzelletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
72. Rooney CM, Smith CA, Ng CYC, Loftin SK, Li CL, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.